New Delhi, Feb. 28 -- Shares of Granules India tumbled nearly 8 percent in intra-day trade on February 28, 2025, after the United States Food and Drug Administration (US FDA) issued a warning letter to the company's Gagillapur facility.

In a regulatory filing, Granules India confirmed that the US FDA issued a warning letter on February 26, 2025, following its inspection in August 2024.

The letter highlighted four key areas of concern, all of which had been previously noted in the FDA Form 483 observations. Granules stated that it has made significant progress in addressing these concerns, with most corrective actions completed, while the remaining ones are on track as per schedule.

Despite the warning, the company clarified that the ma...